Publications by authors named "Marlene Nguimpi-Tambou"
Article Synopsis
- FOLFIRINOX, a chemotherapy combination used for treating pancreatic adenocarcinoma, was analyzed for its effectiveness, measuring progression-free survival (PFS) and overall survival (OS) in patients with metastatic cancer.
- A study involving 136 patients showed a median PFS of approximately 6 months and a median OS of nearly 9 months, identifying factors that could influence survival outcomes.
- The findings suggested that using granulocyte colony-stimulating factor can improve survival rates, while higher doses of oxaliplatin and fluorouracil may have negative impacts on patient outcomes.
Background: Incomplete evaluation of venous invasion has led to conflicting results regarding the prognosis of patients undergoing pancreatectomy with a synchronous venous resection. This study evaluates the prognostic value associated with the presence and the depth of venous invasion in T3 pancreatic adenocarcinoma.
Methods: This study evaluated retrospectively 181 consecutive pancreatoduodenectomies performed for T3N0M0 and T3N1M0 pancreatic adenocarcinomas (stages IIA and IIB) from January 2006 to December 2014.